Aberrant mucin5b expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry

Yan Li, Xiangchun Wang, Ming Hui Ao, Edward Gabrielson, Frederic Askin, Hui Zhang, Qing Kay Li

Research output: Contribution to journalArticle

Abstract

Background: Lung cancer is the number one cause of cancer-related deaths in the United States and worldwide. The complex protein changes and/or signature of protein expression in lung cancer, particularly in non-small cell lung cancer (NSCLC) has not been well defined. Although several studies have investigated the protein profile in lung cancers, the knowledge is far from complete. Among early studies, mucin5B (MUC5B) has been suggested to play an important role in the tumor progression. MUC5B is the major gel-forming mucin in the airway. In this study, we investigated the overall protein profile and MUC5B expression in lung adenocarcinomas, the most common type of NSCLCs. Methods: Lung adenocarcinoma tissue in formalin-fixed paraffin-embedded (FFPE) blocks was collected and microdissected. Peptides from 8 tumors and 8 tumor-matched normal lung tissue were extracted and labeled with 8-channel iTRAQ reagents. The labeled peptides were identified and quantified by LC-MS/MS using an LTQ Orbitrap Velos mass spectrometer. MUC5B expression identified by iTRAQ labeling was further validated using immunohistochemistry (IHC) on tumor tissue microarray (TMA). Results: A total of 1288 peptides from 210 proteins were identified and quantified in tumor tissues. Twenty-two proteins showed a greater than 1.5-fold differences between tumor and tumor-matched normal lung tissues. Fifteen proteins, including MUC5B, showed significant changes in tumor tissues. The aberrant expression of MUC5B was further identified in 71.1% of lung adenocarcinomas in the TMA. Discussions: A subset of tumor-associated proteins was differentially expressed in lung adenocarcinomas. The differential expression of MUC5B in lung adenocarcinomas suggests its role as a potential biomarker in the detection of adenocarcinomas.

Original languageEnglish (US)
Article number15
JournalClinical Proteomics
Volume10
Issue number1
DOIs
StatePublished - 2013

Keywords

  • Expression of mucin5b
  • Immunohistochemistry
  • Lung adenocarcinoma
  • Non-small cell lung cancer
  • Quantitative proteomics and iTRAQ labeling

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Aberrant mucin5b expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry'. Together they form a unique fingerprint.

  • Cite this